Clinical trials: Resistant Major Depression
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation in Pharmaco-naïve Patients With Major Depression
Repetitive transcranial magnetic stimulation (rTMS) has become a safe and efficacious treatment for patients with treatment-resistant depression.
- Trial name
- NAIV (NCT04000022)
- Testing
- intermittent theta burst stimulation (iTBS)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital, Bonn
Major Depressive Disorder
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces hypoxia-related depressive symptoms measured by the…
- Trial name
- NCT02922725
- Testing
- 5-hydroxytryptophan and Creatine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brent Michael Kious, MD, PhD
Depressive Disorder, Major
VA Aripiprazole vs Esketamine for Treatment Resistant Depression
This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs.
- Trial name
- VAST-D II (NCT05554627)
- Testing
- Esketamine, Aripiprazole
- Where
- 26 sites in United States
- Sponsor
- VA Office of Research and Development
Depression
Ketamine Plus Lithium in Treatment-Resistant Depression
The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant…
- Trial name
- NCT01880593
- Testing
- Lithium, Ketamine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder, Metabolic Syndrome
Incidence of Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder
Aim 1 is to study prevalence and 1 year incidence of metabolic syndrome in major depressive disorder and factors correlation. Aim 2 is to study prevalence and 1 year incidence of thyroid dysfunction in major depressive disorder…
- Conditions
- Major Depressive Disorder, Metabolic Syndrome, Thyroid Dysfunction
- Trial name
- NCT01682785
- Volunteers
- 140 people
- Sponsor
- Chiang Mai University
Treatment-Resistant Depression, Major Depressive Disorder
Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression
An observational-comparative study, without interfering with the treatment, based on an operationalized interview.
- Trial name
- NCT06232291
- Where
- Poland
- Volunteers
- 3 people
- Sponsor
- Medical University of Gdansk
Schizophrenia, Schizophrenia and Related Disorders
Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive…
- Conditions
- Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders
- Trial name
- NCT06748950
- Testing
- LCHF Ketogenic Diet, Diet-as-Usual (DAU)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Treatment Resistant Depression, Major Depressive Disorder
The UTHealth Ketamine Project
The primary objective of this study is to determine the effectiveness of serial infusions of intravenous (IV) ketamine in adults with treatment resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02882711
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Treatment Resistant Major Depressive Disorder
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)
- Trial name
- ZYL-730-02 (NCT05438758)
- Testing
- Almond Therapy, Intranasal ketamine (Esketamine), Treatment as Usual
- Sponsor
- Zylorion Health
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Treatment Resistant Depression, Major Depressive Disorder
Clinical Study of GH001 in Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Trial name
- NCT04698603
- Testing
- 5 Methoxy N,N Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- GH Research Ireland Limited
Major Depressive Diorder
qEEG Brain Signature of Depression & Neuromodulation-induced Recovery
This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function.
- Trial name
- NCT06719427
- Testing
- Transcranial Magnetic Stimulation
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression
PCS in Severe Treatment Resistant Depression
This research study is designed to test if electrical stimulation of the surface of the brain in the frontal region will help treat depressive symptoms.
- Trial name
- NCT04124341
- Testing
- Prefrontal Cortical Stimulation (PCS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Minnesota
Major Depression
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Background: Drugs and talk therapy help treat depression, but these treatments usually take quite a bit of time to work. Ketamine is a fast-acting antidepressant, but it has side effects like unusual dreams and experiences.
- Trial name
- NCT02484456
- Testing
- AV 101 (4-Chlorokynurenine)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression Severe
Brain Stimulation for Severe Depression
Chronic intracalvarial cortical stimulation is a minimally invasive method involving the neurosurgical placement of an electrode above the inner table of the skull.
- Trial name
- NCT05393622
- Testing
- INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Inner Cosmos Inc
Major Depression
Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET
This study aims at evaluating the effect of electroconvulsive therapy in treatment-resistant depressed patients on the major serotonin degrading enzyme in the human brain using neuroimaging methods, the monoamine oxidase A.
- Trial name
- NCT02379767
- Testing
- Electroconvulsive therapy, Positron emission tomography of the brain using [11C]harmine, Structural magnetic resonance imaging
- Where
- Austria
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Biomarker-Guided Antidepressant Selection
Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.
- Conditions
- Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine
- Trial name
- BioSelect (NCT07680140)
- Testing
- TMS, Ketamine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Weill Medical College of Cornell University
Depression
Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression
About 30% of patients with major depression are treatment resistant to pharmacological treatment. In the search for new methods to treat depression a great interest has been put into the use of electromagnetic fields.
- Trial name
- NCT00287703
- Testing
- Pulsating Electro-Magnetic Fields
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Hillerod Hospital, Denmark
Depression, Major Depressive Disorder
eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
This pilot randomized controlled trial seeks: (1) to determine the preliminary efficacy of our modernized collaborative care intervention for depression in improving the diabetes risk markers of hemoglobin A1c and insulin…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT04437485
- Testing
- Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Indiana University
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center